We are live on ! Find out more

BridgeBio Oncology

BBOT

Market cap $215M

2.68 USD

-0.04

1.47%

At close Updated Oct 21, 4:00 PM EDT

1 day

-1.47%

5 days

-7.59%

1 month

-42.49%

3 months

-69.27%

6 months

-71.67%

Year to date

-78.19%

1 year

-75.68%

5 years

-73.7%

10 years

-73.7%

About: BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.

Employees: 88

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 83.3%

Negative 16.7%

BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff

BridgeBio Oncology Therapeutics is rated Speculative Buy, with a risk-adjusted valuation of $3.76 per share, implying 33% upside. BBOT's pipeline, led by BBO-11818, targets multiple KRAS mutations and offers potential differentiation over existing KRAS G12C inhibitors. Recent strategic shifts and clinical updates triggered a 68% decline in BBOT's stock, reflecting concerns about commercial scope and execution.

BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new clinical data for KRASG12C inhibitor BBO-8520 and the strategic prioritization of (i) BBO-8520 in combination with checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced non-small cell lung cancer (NSCLC) patients and (ii) BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.

BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers

BBOT to Participate in Upcoming Investor Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.

BBOT to Participate in Upcoming Investor Healthcare Conferences

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203 Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models Cash runway expected to fund operations into 2028 SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate and 100% disease control in KRAS G12C NSCLC, exceeding results from approved competitors. Further mature data readouts for BBOT's pipeline are expected in 2H26, representing key catalysts for share price re-rating and future funding opportunities.

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

See News Rankings

Price charts implemented using Lightweight Charts™